Documenti di Didattica
Documenti di Professioni
Documenti di Cultura
4.1 DOMPERIDONE1-16
Drug Interactions This medication enhances movement in the digestive tract, it may
affect the absorption and action of other medications. Opioid
analgesics and antimuscarinics antagonize its effects.
4.2 GLICLAZIDE1,2,17-23
Structural Formula
Kyron is derived from the polymer cross-linked polyacrylic used in the pharmaceutical
industry to mask the taste of bitter medicine to achieve stability and drugs. It is white to off white
fine powder, swellable in water. KYRON T 314 is derived from cross linked polymer
of polycarboxylic acid as per USP/NF and has a K+ ionic form. It is a very high purity
polymer used in pharmaceutical formulation as a super fast disintegrant as well as
dissolution improver in solid dosage form like tablet, capsule, pellets etc. It is suitable for the
both wet granulation as well as direct compression system for tablet formulations. Different
grades of Kyron with specifications showed in table 4.1.
KYRON GRADES
Specification T-104 T-114 T-134 T-154 T-159 T-123
Pharmacopoeia In house In house Polacrilin Sodium In house In house
potassium polystyrene
USP Sulphonate
USP
Type Weak acid Weak acid Weak acid Strong acid Strong acid Weak base
Functionality -COO- -COO- -COO- -SO-3 -SO-3 Secondary
amine
Ionic Form Hydrogen Hydrogen Potassium Sodium Hydrogen Free base
Matrix Polyacrylic Polyacrylic Polyacrylic Polystyrene Polystyrene Polystyrene
copolymer copolymer copolymer copolymer copolymer copolymer
Moisture content <10 <5 <10 <10 <10 <10
(%)
Appearance White to off White to off White to off off White to off White to White to off
white free white free white free golden golden white free
flowing flowing flowing yellow free yellow free flowing
powder powder powder flowing flowing powder
powder powder
Description It is a very fine, light white, precipitated or milled, low bulk density,
having a faint odor of stearic acid and a characteristic taste.
Applications It is used as lubricant in tablet and capsule manufacture in
concentration of 0.25% and 5.0%w/w.
Solubility Practically insoluble in ethanol, ether, slightly soluble in warm
benzene and warm ethanol (95%), sparingly soluble in water.
REFERENCES
14. Olin RB, Hebel SK, Connell SI. Drug facts and comparisons. St Louis, Wolters Kluwer,
1991; 2561.
15. Ahmad N, Keith-Ferris J, Gooden E. Making a case for domperidone in the treatment of
gastrointestinal motility disorders. 2006; 6(6): 571-6.
16. http://www.drugbank.ca/drugs/DB01120.
17. http://www.drugs.com/mmx/gliclazide.html.
18. Rang HP, Dale MM, Ritter JM, Flower RJ. Pharmacology sixth edition, Churchill
Livingstone Elsevier, UK. 2007; 393.
19. Goodman & Gilmans: The pharmacological basis of therapeutics, eleventh edition.,
McGraw-Hill Medical Publishing Division. 2006; 986, 1002 and 1632-1637.
20. Ballagi-Pordny G, Kszeghy A, Koltai MZ, Aranyi Z, Pogtsa G. Divergent cardiac
effects of the first and second generation hypoglycemic sulfonylurea compounds.
Diabetes Res. Clin. Pract.1990; 8 (2): 10914.
21. Shimoyama T, Yamaguchi S, Takahashi K. Gliclazide protects 3T3L1 adipocytes against
insulin resistance induced by hydrogen peroxide with restoration of GLUT4
translocation. Metabolism - Clinical and Experimental. 2006; 55 (6): 72230.
22. Rieutord A, Stupans I, Shenfield GM, Gross AS. Gliclazide hydroxylation by rat
liver microsomes. Xenobiotica. 1995; 25: 134554.
23. Campbell DB, Lavielle R, Nathan C. The mode of action and clinical pharmacology of
gliclazide. Diabetes Res Clin Pract. 1991;14 (2): S21-36.
24. Rowe RC, Sheskey PJ, Quinn ME. Handbook of Pharmaceutical excipients. Sixth
edition. Pharmaceutical Press and American pharmacists Association.
2009;48,118,129,134,206,404,424,57,581,663 and 728.
25. http://chemicalland21.com/industrialchem/organic/polyethylene%20glycol.htm.
26. http://en.wikipedia.org/wiki/Polyethylene_glycol.
27. Indian Pharmacopeia. Indian Pharmacopeial commission Ghaziabad;Vol-III-2007;
300,744,1337,1391,1779,3365.
28. The United State Pharmacopoeia. Asian edition.2006; 1311,1334,2054,3277,3306,3391.
29. http://en.wikipedia.org/wiki/Polyvinylpyrrolidone.
30. http://www.pformulate.com/nastgly.htm.
31. http://www.pharmatechnologyindex.com/Products/Tablet-Section/Coating-
Material/Kyron-T-314-50207652590100254.html.
32. http://www.corelpharmachem.com/kyron.htm.
33. Kearsley MW, Deis RC. Sorbitol and Mannitol. In Sweeteners and Sugar Alternatives in
Food Technology; Ames: Oxford, 2006; 249-249-261.
34. Song SH, Vieille C. Recent advances in the biological production of mannitol. Appl
Microbiol Biotechnol. 2009; 84: 5562.
35. Ghoreishi SM, Shahrestani RG. Innovative strategies for engineering mannitol
production. Trends Food Sci. Technol. 2009; 20: 263-270.
36. The Merck Index.11th ed. Rahway, NJ: Merck & Co. 859.
37. Harry G. Analytical profiles of drug substances and excipients: Aspartame. Academic
Press Britain. 2002; 15-20.
38. Magnuson BA, Burdock GA, Doull J. Aspartame: a safety evaluation based on current
use levels, regulations, and toxicological and epidemiological studies. Critical Reviews in
Toxicology. 2007; 37 (8): 629727.
39. FDA's SCOGS database; Magnesium stearate, Report No. 60, 1979.; ID Code: 557-
040;http://www.accessdata.fda.gov/scripts/fcn/fcnDetailNavigation.cfm?rpt=scogsListing
&id=198 Accessed July 18, 2011.(mg stearate).
40. Dave RH. Overview of pharmaceutical excipients used in tablets and capsules. Drug
Topics(online).Advanstar.10/24/2008 http://drugtopics.modernmedicine.com/drugtopics/
Top+News/Overview-of-pharmaceutical-excipients-used-in-tabl/ArticleStandard/Article/
detail/561047 . Accessed 08/19/2011.(mg stearate).